Financials NurExone Biologic Inc. Deutsche Boerse AG
Equities
J90
CA67059R1091
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 EUR | -0.83% | +5.22% | +183.04% |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 12.25 | 10.75 | 33.86 | - | - |
Enterprise Value (EV) 1 | 12.25 | 10.75 | 33.86 | 33.86 | 33.86 |
P/E ratio | -1.32 x | -2.75 x | -6.3 x | -6.3 x | -10.1 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 42,855 | 48,250 | 67,162 | - | - |
Reference price 2 | 0.2858 | 0.2228 | 0.5041 | 0.5041 | 0.5041 |
Announcement Date | 3/30/23 | 4/2/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -3.657 | -4.62 | -4.75 | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -3.639 | -4.669 | -4.737 | - |
Net income 1 | -8.169 | -3.639 | -4.669 | -4.737 | - |
Net margin | - | - | - | - | - |
EPS 2 | -0.2160 | -0.0810 | -0.0800 | -0.0800 | -0.0500 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/30/23 | 4/2/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.06 | -1.164 | -0.716 | -0.92 | -1.1 | -1.2 | -1.4 | -1.05 | -1.1 |
Operating Margin | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.04 | -1.158 | -0.737 | -0.922 | -1.101 | -1.201 | -1.401 | -1.035 | -1.101 |
Net income 1 | -1.04 | -1.158 | -0.737 | -0.922 | -1.101 | -1.201 | -1.401 | -1.035 | -1.101 |
Net margin | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.0240 | -0.0260 | -0.0150 | -0.0160 | -0.0200 | -0.0200 | -0.0200 | -0.0200 | -0.0200 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/28/23 | 11/24/23 | 4/2/24 | 5/29/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 3/30/23 | 4/2/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- NRX Stock
- J90 Stock
- Financials NurExone Biologic Inc.